Q-VD-OPH Inhibitor Peptide

Q-VD-OPH is a cell permeable caspase peptide inhibitor. Caspase inhibitors irreversibly bind to the catalytic site of caspase proteases and inhibit apoptosis. Caspase inhibitors may be broad spectrum, inhibiting multiple caspases, or may preferentially inhibit particular caspases. Z-VAD-FMK, BOC-D-FMK, and Q-VD-OPH are examples of broad spectrum or pan caspase inhibitors. In contrast Z-DEVD-FMK preferentially inhibits caspases 3 and 7, Z-IETD-FMK preferentially inhibits caspase 8, Z-LEHD-FMK preferentiailly inhibits caspase 9. Z-FA-FMK is considered to be a negative control for FMK based caspase inhibitors.

Mass Spec: M+1=514.1
Chromatography: TLC:Rf: 0.4 Single Spot, EtOAC:6, ACOH:0.1
H NMR: All functional groups are present

Q-Val-Asp(non-omethylated)-OPH, also known as Q-VD(non-omethylated)-OPH. Molecular Weight: 513

Q-VD-OPH is a novel, irreversible, pan caspase inhibitor specifically designed for in vivo and in vitro research. Q-VD-OPH is widely cited in the literature, and researchers should refer to the literature for additional information about the various species that Q-VD-OPH has been used for.For in vitro applications, Q-VD-OPH is typically used at final working concentration of 10-100 uM. The variability depends on model system, including cell type, culture, properties, and type of apoptosis induction treatments. Each researcher should empirically establish optimal working concentrations for their in vitro model system.
For in vivo applications, the recommended dose of Q-VD-OPh is 20 mg/kg. The caspase inhibitor is administered IP in 80-100% DMSO. Doses of up to 120 mg/kg have been used in mice without toxic effects (Melnikov and Vyacheslav, 2002; Patil and Sharma, 2004). Each researcher should empirically establish optimal doses for their animal model system. Use in functional reported in scientific literature (PMID: 24068677)